Sanofi will launch a cash tender offer for Blueprint ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Shares of Blueprint Medicines Corp (NASDAQ:BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (NASDAQ:SNY) in a deal valued at approximately $9 ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.